全文获取类型
收费全文 | 40025篇 |
免费 | 3318篇 |
国内免费 | 165篇 |
专业分类
耳鼻咽喉 | 639篇 |
儿科学 | 956篇 |
妇产科学 | 692篇 |
基础医学 | 4917篇 |
口腔科学 | 912篇 |
临床医学 | 3890篇 |
内科学 | 9028篇 |
皮肤病学 | 472篇 |
神经病学 | 3309篇 |
特种医学 | 1328篇 |
外科学 | 6677篇 |
综合类 | 746篇 |
一般理论 | 25篇 |
预防医学 | 3120篇 |
眼科学 | 1031篇 |
药学 | 2888篇 |
中国医学 | 127篇 |
肿瘤学 | 2751篇 |
出版年
2023年 | 204篇 |
2022年 | 410篇 |
2021年 | 916篇 |
2020年 | 514篇 |
2019年 | 806篇 |
2018年 | 931篇 |
2017年 | 727篇 |
2016年 | 722篇 |
2015年 | 800篇 |
2014年 | 1259篇 |
2013年 | 1755篇 |
2012年 | 2613篇 |
2011年 | 2602篇 |
2010年 | 1440篇 |
2009年 | 1369篇 |
2008年 | 2368篇 |
2007年 | 2519篇 |
2006年 | 2638篇 |
2005年 | 2627篇 |
2004年 | 2412篇 |
2003年 | 2447篇 |
2002年 | 2275篇 |
2001年 | 549篇 |
2000年 | 538篇 |
1999年 | 581篇 |
1998年 | 561篇 |
1997年 | 448篇 |
1996年 | 407篇 |
1995年 | 325篇 |
1994年 | 295篇 |
1993年 | 254篇 |
1992年 | 349篇 |
1991年 | 314篇 |
1990年 | 310篇 |
1989年 | 272篇 |
1988年 | 244篇 |
1987年 | 225篇 |
1986年 | 225篇 |
1985年 | 217篇 |
1984年 | 248篇 |
1983年 | 201篇 |
1982年 | 220篇 |
1981年 | 209篇 |
1980年 | 163篇 |
1979年 | 152篇 |
1978年 | 160篇 |
1977年 | 143篇 |
1976年 | 111篇 |
1974年 | 125篇 |
1973年 | 122篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
35.
Dr. Barbara McGee Hughes Pharm.D. Dr. Ralph E. Small Pharm.D. Dr. Douglas Brink Pharm.D. Dr. Norma D. McKenzie M.D. 《Pharmacotherapy》1997,17(1):113-120
Study Objective . To evaluate the effects of flurbiprofen therapy on the pharmacokinetics of lithium. Design . Placebo-controlled, single-blind, crossover study. Setting . University-affiliated hospital. Patients . Eleven healthy women with bipolar disorder. Interventions . The subjects received therapeutic doses of lithium administered as an immediate-release capsule every 12 hours. In addition, they received one placebo tablet every 12 hours during phase I and flurbiprofen 100 mg every 12 hours during phase II of the study. Measurements and Main Results . Steady-state pharmacokinetic parameters were measured for each phase. Lithium trough plasma concentration (Cmin) and area under the curve were statistically significantly increased (p<0.05) when patients received flurbiprofen. Flurbiprofen also caused decreases in lithium clearance and 24-hour lithium urine excretion, although the changes did not reach statistical significance. Clinically significant increases in Cmin appeared to be associated with a greater than 1000-μg/24 hour decrease in urinary excretion of prostaglandin E2. Conclusion . Patients with clinically normal renal function may experience an increase in lithium levels with the initiation of flurbiprofen therapy. 相似文献
36.
Dr. James Hui Ph.D. Dr. Yow-Ming C. Wang Ph.D. Dr. Appavu Chandrasekaran Ph.D. Dr. Douglas R. Geraets Pharm.D. Dr. James H. Caldwell M.D. Dr. Larry W. Robertson Ph.D. Dr. Richard H. Reuning Ph.D. 《Pharmacotherapy》1994,14(5):607-612
Study Objective . To compare digoxin tablets and liquid-filled capsules with respect to excretion of the drug and its metabolites in urine and feces at steady state. Design . A randomized, crossover trial, each period lasting 3 weeks, with no washout period. Setting . A university hospital. Patients . Six patients, five of whom were elderly, with histories of gastrointestinal disorders, such as hypochlorhydria, intestinal bacterial overgrowth, and inflammatory bowel disease. Interventions . The patients received digoxin once/day in either tablet or capsule form for 3 weeks, and then were switched to the other formulation. Total urinary and fecal excretion from the last 3 days of each regimen were analyzed for the drug and metabolites. Measurements and Main Results . No statistically significant differences were found between tablets and capsules in recovery of digoxin or its metabolites in urine or feces (p=0.05). One subject had a 4-fold increase in urinary drug excretion and 50% decrease in fecal excretion after taking the capsules compared with tablets. Intersubject variability in extent and type of metabolite excretion was greater than intrasubject variability. Conclusions . Fecal analyses may be an accurate way to classify patients as formers of digoxin reduction products. 相似文献
37.
Haiyung Cheng Jules I. Schwartz Charles Lin Raju D. Amin James R. Seibold Kenneth C. Lasseter David L. Ebel Dominick J. Tocco J. Douglas Rogers 《Biopharmaceutics & drug disposition》1994,15(5):409-418
MK-679 (R(?)-3-((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)(3-(dimethylamino)-3-oxopropyl)thio)methyl)thio(propanoic acid) is a potent and specific LTD4-receptor antagonist. The disposition of MK-679 was investigated in a three-way crossover study in 12 healthy males receiving single intravenous doses of 75, 250, and 500 mg of MK-679. A greater than proportional increase in the area under the plasma concentration—time curve of MK-679 was observed with increase in dose. The plasma concentration data for each subject fitted well to the differential equations for a two-compartment model with linear tissue distribution and Michaelis-Menten elimination from the central compartment, indicating that the elimination of MK-679 in humans is saturable. In a previous study, the disposition of MK-679 in humans was also dose-dependent when given together with its S(+)-isomer, L-668,018. Thus, the disposition of MK-679 in humans is dose-dependent regardless of the presence of its stereoisomer. Also, the bioavailability of MK-679 was determined in six healthy males receiving simultaneously an oral dose of 250 mg of MK-679 and intravenous infusion of 1 mg 14C-MK-679. Results of this study indicate that the oral bioavailability of MK-679 is nearly quantitative. 相似文献
38.
SUMMARY A case congenital dislocation of both knees and dislocation of the left hip in an infant whose mother had a chronic amniotic fluid leakage after mid-trimester amniocentesis. 相似文献
39.
40.